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Simple Summary: Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung
cancer, but few studies have reported on patient-reported outcomes (PROs) outside the context of a
clinical trial. The goal of the current study was to assess PROs in patients participating in the GO2
Foundation’s Lung Cancer Registry who reported receiving atezolizumab, durvalumab, nivolumab,
or pembrolizumab. Internationally, 226 patients (mean age 61, 75% female) participated. Patients
reported worse quality of life than U.S. population and cancer normative samples. The most common
moderate to severe adverse events during ICI treatment were fatigue (41%), aching joints (27%), and
aching muscles (20%). Due to toxicity, 25% reported a treatment delay, 11% an emergency room visit,
and 9% a hospitalization. This study is among the first to our knowledge to report on PROs of ICIs
outside the context of a clinical trial. Results suggest higher rates of adverse events than previously
reported in clinical trials.
Abstract: Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, but
few studies have reported on patient-reported outcomes (PROs) outside the context of a clinical
trial. The goal of the current study was to assess PROs in participants of a lung cancer registry who
had been treated with an ICI. Patients participating in the GO2 Foundation’s Lung Cancer Registry
who reported receiving atezolizumab, durvalumab, nivolumab, or pembrolizumab were invited to
participate in a survey about their experiences during treatment. Quality of life was evaluated using
the Functional Assessment of Cancer Therapy–General (FACT-G). Common symptomatic adverse
events were evaluated using an item bank generated for ICIs. Internationally, 226 patients (mean
age 61, 75% female) participated. Patients reported worse quality of life at the time of assessment
than U.S. population and cancer normative samples. The most common moderate to severe adverse
events during ICI treatment were fatigue (41%), aching joints (27%), and aching muscles (20%). Due
to toxicity, 25% reported a treatment delay, 11% an emergency room visit, and 9% a hospitalization.
This study is among the first to our knowledge to report on PROs of ICIs outside the context of a
clinical trial. Results suggest higher rates of adverse events than previously reported in clinical trials.
Keywords: antineoplastic agents; immunological; programmed cell death receptor 1; lung neoplasms;
quality of life; patient-reported outcome measures
1. Introduction
Immune checkpoint inhibitors (ICIs) have generated widespread excitement for their
ability to significantly prolong survival in cancers with poor prognoses. Non-small-cell lung
cancer (NSCLC) has emerged as a target of immune-based therapies, with some patients
with advanced NSCLC experiencing durable remissions and prolonged survival [1,2].
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The success of ICIs in slowing disease progression comes with the cost of toxicity,
however. All checkpoint inhibitors can potentially induce immune-related toxicities in any
organ system. Immune-related toxicities occur in up to 70% of patients treated with PD-
1/PD-L1 antibodies [3,4]. Up to 16% of patients experience grade 3 or higher toxicities [3,4].
The single-agent anti-PD-1 antibodies, such as nivolumab and pembrolizumab, have fewer
side effects than combination ipilimumab/nivolumab (grade 3 or 4 adverse events in
10–15% versus grade 3 or 4 adverse events in 55%). Common toxicities of PD-1/PD-L1
antibodies include fatigue, diarrhea, rash, pruritus, decreased appetite, hepatic toxicities,
and endocrinopathies [3,4].
There is increasing awareness of the importance of collecting patient-reported outcome
(PRO) data in oncology [5–7]. PROs can be defined as “reports of the status of a patient’s
health condition that come directly from the patient, without interpretation of the patient’s
response by a clinician or anyone else” [5]. PROs can be categorized as disease symptoma-
tology, treatment side effects, and quality of life (i.e., how symptoms and side effects impact
daily functioning) [5]. PROs are particularly relevant as an indicator of clinical benefit
when new therapies have a modest impact on survival. PROs demonstrate significant
associations with survival and other important outcomes, including performance status,
adherence, and treatment discontinuation [8–11]. PRO data can also contribute to more
accurate adverse event reporting in clinical trials, as data suggest that concordance between
clinicians’ and patients’ reports of side effects is low [12,13]. PRO data collection gives a
voice to patients, especially long-term survivors whose toxicity is generally not reported
in clinical trials. Dissemination of PRO data can help future patients to make informed
decisions about their care and contribute to shared decision-making [14].
Numerous phase III trials of ICIs have reported favorable quality of life in patients
treated with ICIs relative to those treated with standard of care (e.g., chemotherapy).
Nevertheless, there are notable omissions in the current literature. First, there are few
published studies of PROs in patients treated with ICIs outside the context of a clinical
trial [15–19]. This real-world evidence is important because patients treated on a clinical
trial tend to be younger, healthier, and have higher socioeconomic status than those treated
in the community setting [20,21]. In addition, clinical trials have reported almost exclusively
on overall quality of life or disease-specific symptomatology (e.g., shortness of breath in
lung cancer) but not patient-reported symptomatic toxicities of ICIs, such as diarrhea and
rash. Omission of treatment-specific patient-reported toxicities may bias PRO findings
against standard of care. The FDA noted the importance of studying treatment-specific
PROs in its Guidance for Industry document in 2009 [22].
Patient registries administered by advocacy groups offer a way to rapidly address
these knowledge gaps with little cost. Although population-based cancer registries are
common, those developed by advocacy groups offer the opportunity to reach a subgroup
of engaged patients to generate hypotheses to be tested in more representative clinical
settings. In collaboration with the GO2 Foundation for Lung Cancer (previously the Bonnie
J. Addario Lung Cancer Foundation), we prospectively collected PRO data from patients
participating in the Lung Cancer Registry (www.lungcancerregistry.org) who reported
receiving treatment with a PD-1 inhibitor (i.e., atezolizumab, durvalumab, nivolumab,
pembrolizumab). The goals of the study were to: (1) evaluate the feasibility and accept-
ability of using patient registries to collect PRO data of novel anti-cancer agents, and (2)
evaluate ICI-specific patient-reported toxicities and overall quality of life in patients treated
with ICIs in the real-world setting. The study was intended to describe the overall patient
experience rather than attribute PROs to a specific cause (e.g., treatment side effects versus
disease symptomatology). Because the study was intended to be exploratory, no a priori
hypotheses were generated.
2. Results
Data were collected between January 2018 and December 2019. In total, 258 of 646
(40%) of eligible patients responded to the survey invitation, of which 226 of 258 (87%) pa-
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tients who started the survey completed it. Sociodemographic and clinical characteristics of
the 226 participants are described in Table 1. The majority of participants were female (75%),
White (90%), and from the United States (89%). Patients reported an average Charlson
Comorbidity Index score of 3. Overall, 111 patients received pembrolizumab, 81 nivolumab,
29 durvalumab, and 13 atezolizumab, with eight patients reporting receipt of more than
one. For a plurality of patients (47%), the duration of treatment with an ICI was 2–6 months.
Due to toxicity, 25% reported a delay in treatment, 11% reported an emergency room (ER)
visit, and 9% reported being admitted to the hospital. Patients treated with nivolumab
reported significantly longer time on treatment than those treated with durvalumab or
pembrolizumab and patients treated with atezolizumab reported significantly longer time
on treatment than those treated with durvalumab (p < 0.001). Other sociodemographic and
clinical characteristics did not significantly differ by ICI regimen (p values ≥ 0.07). Quality
of life scores are also shown in Table 1. There were no group differences in overall quality
of life or quality of life subscales at the time of assessment. Conversion of Functional
Assessment of Cancer Therapy–General (FACT-G) subscale scores in the current sample to
European Organisation for Research and Treatment of Cancer Quality of Life of Cancer
Patients questionnaire (EORTC QLQ-C30) subscale scores yielded the following values:
physical wellbeing (M = 73.86, 95%CI: 71.49 to 76.22), role/functional wellbeing (M = 56.61,
95%CI: 53.25 to 59.98), and emotional wellbeing (M = 57.23, 95% CI: 54.51 to 59.96) sub-
scales. These values were significantly lower than those reported in the PACIFIC trial at
48 weeks post-initiation of durvalumab: physical functioning (M = 82.9), role functioning
(M = 78.9), and emotional functioning (M = 84.8) [23].
Table 2 lists the frequency of symptomatic toxicities during treatment with ICIs. Those
of any severity reported by a majority of the sample included fatigue (85%), aching joints
(63%), aching muscles (57%), insomnia (56%), shortness of breath (51%), itching (50%), and
skin dryness (50%). The three most common moderate-to-severe symptomatic toxicities
were fatigue (41%), aching joints (27%), and aching muscles (20%).
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Table 1. Sociodemographic and clinical characteristics and patient-reported outcomes by immune checkpoint inhibitor received. Note: Some percentages do not equal 100 due to sporadic
missing data.
Variable All (n = 226) Durvalumab (n = 29) Nivolumab (n = 81) Pembrolizumab (n = 111) Atezolizumab (n = 13) p Value
Age: M (SD) years 61.16 (10.52) 61.48 (9.13) 61.24 (10.29) 61.02 (10.79) 56.69 (10.00) 0.37
Gender: n (%) female 170 (75%) 23 (79%) 61 (75%) 81 (73%) 11 (85%) 0.76
Race: n (%) white 200 (90%) 27 (93%) 75 (94%) 94 (86%) 12 (92%) 0.37
Comorbidities: M (SD) 2.86 (1.62) 2.79 (0.94) 3.00 (1.75) 2.78 (1.65) 2.85 (1.52) 0.82
Time on Treatment: n (%) <0.001
≤1 month 23 (10%) 3 (10%) 5 (6%) 14 (13%) 1 (8%)
2–6 months 105 (47%) 18 (62%) 30 (37%) 54 (50%) 7 (58%)
7–12 months 35 (16%) 7 (24%) 9 (11%) 21 (19%) 0 (0%)
13–24 months 30 (14%) 1 (3%) 12 (15%) 17 (16%) 2 (17%)
>24 months 29 (13%) 0 (0%) 25 (31%) 2 (2%) 2 (17%)
Treatment delay due to toxicity: n (%) 56 (25%) 10 (34%) 20 (25%) 24 (22%) 3 (23%) 0.33
ER visit due to toxicity: n (%) 26 (12%) 2 (7%) 8 (10%) 15 (14%) 1 (8%) 0.82
Hospitalization due to toxicity: n (%) 20 (9%) 1 (3%) 4 (5%) 13 (12%) 2 (15%) 0.31
FACT-G Total: M (SD) 74.08 (17.28) 74.21 (19.96) 75.39 (16.21) 73.72 (16.86) 65.77 (16.30) 0.31
Physical 21.37 (5.68) 21.41 (5.13) 21.94 (5.73) 20.87 (6.04) 20.31 (6.51) 0.59
Functional 16.74 (6.34) 17.24 (7.05) 17.14 (5.63) 16.52 (6.57) 13.92 (6.01) 0.36
Emotional 16.39 (4.96) 16.72 (4.78) 17.35 (4.46) 15.98 (5.11) 13.92 (5.33) 0.07
Social 19.54 (6.02) 18.82 (8.00) 19.24 (5.73) 20.08 (5.44) 17.62 (6.96) 0.42
PROMIS Depression 4a: M (SD) 7.11 (3.14) 7.00 (3.23) 6.84 (2.91) 7.13 (3.28) 8.50 (2.94) 0.39
Note: Eight patients reported receipt of multiple immune checkpoint inhibitors. FACT-G: Functional Assessment of Cancer Therapy–General. Comorbidities represent the Charlson Comorbidity Index score.
p-values correspond to ANOVA or chi-square tests of all groups, as appropriate.
Table 2. Most common symptomatic immune-related adverse events (irAEs). Note: Some percentages do not equal 100 due to sporadic missing data. Any irAE was defined as patients
reporting “a little bit,” “somewhat,” “quite a bit,” or “very much.” A moderate to severe irAE was defined as patients reporting “quite a bit” or “very much.”
Symptom Any Severity n (%) Moderate-Severe n (%) Missing n Responses n
Fatigue 190 (85%) 92 (41%) 10 224
Aching joints 137 (63%) 58 (27%) 16 218
Aching muscles 122 (57%) 43 (20%) 21 213
Insomnia 122 (56%) 38 (18%) 17 217
Shortness of breath 109 (51%) 27 (13%) 20 214
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Table 2. Cont.
Symptom Any Severity n (%) Moderate-Severe n (%) Missing n Responses n
Itching 108 (50%) 40 (18%) 16 218
Skin dryness 108 (50%) 38 (18%) 20 214
Back pain 103 (48%) 28 (13%) 19 215
Problems with memory 100 (47%) 18 (8%) 21 213
Problems with concentration 98 (46%) 14 (7%) 20 214
Numbness or tingling in hands or feet 98 (45%) 27 (12%) 17 217
Constipation 96 (44%) 26 (12%) 17 217
Cough (new or worsening) 94 (44%) 23 (11%) 19 215
Change in the way food tastes 86 (40%) 29 (13%) 19 215
Headache 85 (39%) 20 (9%) 18 216
Bone pain 84 (39%) 29 (14%) 21 213
Feeling bloated 83 (39%) 29 (14%) 20 214
Diarrhea 81 (38%) 25 (12%) 19 215
Frequent urination 80 (38%) 28 (13%) 22 212
Weakness in arms or legs 78 (37%) 18 (9%) 23 211
Nausea 79 (36%) 24 (11%) 17 217
Loss of appetite 77 (36%) 23 (11%) 21 213
Reflux or heartburn 77 (36%) 25 (12%) 22 212
Dizziness 74 (35%) 6 (3%) 22 212
Abdominal pain 73 (34%) 12 (6%) 22 212
Rash 72 (33%) 32 (15%) 18 216
Blurred vision 72 (34%) 14 (7%) 21 213
Problems with balance or coordination 70 (33%) 12 (6%) 19 215
Increased skin sensitivity to heat, cold, touch, or sunlight 67 (31%) 26 (12%) 19 215
Hives 65 (30%) 22 (10%) 19 215
Wheezing 63 (30%) 18 (8%) 21 213
Chest pain 61 (29%) 9 (4%) 21 213
Easy bruising or bleeding 59 (27%) 14 (6%) 18 216
Mouth sores 44 (20%) 9 (4%) 18 216
Shivering or shaking chills 41 (20%) 9 (4%) 24 210
Arm or leg swelling 36 (17%) 10 (5%) 24 210
Swelling in the face 27 (13%) 3 (1%) 22 212
Vomiting 18 (9%) 7 (3%) 27 207
Blood in stool 15 (7%) 3 (1%) 23 211
Vitiligo 10 (5%) 2 (1%) 23 211
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3. Discussion
This registry-based study with the GO2 Foundation for Lung Cancer Foundation
is among the first to our knowledge to report on PROs in lung cancer patients receiv-
ing ICIs outside the context of a clinical trial. Registry-based studies are an ideal way
to engage patients in hypothesis-generating, quantitative studies. Hypotheses can then
be tested in more representative patient samples. The current study demonstrated the
feasibility and acceptability of a registry-based approach, with 226 patients recruited in
24 months and 87% of patients who started the survey completing it. Results indicated
no differences by ICI regimen in overall quality of life or subscales. Study participants
reported worse overall quality of life, emotional wellbeing, and functional wellbeing than
U.S. population norms [24], as might be expected in advanced lung cancer patients. There
were no differences in the physical and functional wellbeing of the sample compared
to U.S. population norms. Interestingly, the sample also reported worse quality of life
overall and in all domains compared to a normative sample of cancer patients [24]. These
findings are consistent with studies in the pre-checkpoint era reporting greater supportive
care needs and higher distress in advanced lung cancer patients compared to patients
with other cancer diagnoses [25,26]. Quality of life in this study was also significantly
worse than that reported at 48 weeks in a recent clinical trial of patients with lung cancer
treated with durvalumab [23]. Our findings may be due to the sample composition; for
example, perhaps registry participants have higher symptomatology than patients as a
whole, particularly clinical trial participants. The current study also noted higher rates of
any and moderate-to-severe symptomatic toxicities as compared to clinical trials. These
findings are consistent with previous studies suggesting that provider-rated adverse events
on clinical trials tend to underestimate PROs [27]. Although it has been widely noted that
fatigue and rash are common symptomatic toxicities of ICIs [28,29], there has been less
attention focused on arthralgias and myalgias. Data from studies of other patients with
arthralgias and myalgias (e.g., in breast cancer patients treated with aromatase inhibitors)
suggest that these side effects can be distressing and compromise daily functioning [30].
Thus, these toxicities deserve increased attention in the context of ICIs.
The current study is characterized by several strengths, including an international
sample of real-world lung cancer patients that was heterogeneous in terms of ICI received,
a validated measure of quality of life, and appropriate statistical analyses. Study limitations
should also be noted, however. As this registry was not population-based, registry partici-
pants on the current study should not be considered representative of the larger population
of advanced lung cancer patients treated with an ICI. Bias and non-representativeness
may be exacerbated by putative non-representativeness of the subset of registry partic-
ipants who completed the survey. Thus, it is unknown whether patients who did not
respond to the survey invitation would have reported similar quality of life and immune-
related adverse events to those patients who did provide data. Results are intended to be
hypothesis-generating and should be investigated further in more representative patient
samples. In addition, the cross-sectional survey asked about symptomatic toxicities during
treatment with ICIs, which could have been current or completed months or years pre-
viously. Consistent with other studies of patient-reported outcomes, study participants
may have been subject to recall bias that made it difficult to accurately remember what
they were experiencing during treatment with ICIs. In this particular context, we believe
retrospective data are valuable because they provide a first look at the prevalence of memo-
rable (and likely impactful) symptomatic toxicities over the course of treatment. Thus, they
provide important preliminary data to be further investigated in prospective, longitudinal
studies. A related limitation is that patients were heterogeneous in terms of which current
treatment they might be receiving. Thus, we were unable to partition the relative influence
of long-term and late effects of ICIs on quality of life from the impact of current treatments.
Findings of worse quality of life compared to U.S. population and cancer normative data
suggest the importance of future follow-up studies to understand lung cancer survivorship
after ICI treatment. In addition, because all data were reported by patients, we did not
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have access to electronic medical records that would provide additional clinical insight into
patients’ experiences, e.g., tumor grade, number of metastatic sites, tumor progression, etc.
Lastly, the sample was largely composed of White Americans. Additional studies are
needed in diverse samples.
4. Materials and Methods
4.1. Participants
To be eligible, participants were: (1) age 18 or older, (2) diagnosed with lung cancer
or a caregiver to a person diagnosed with lung cancer, (3) treated with or a caregiver to a
patient treated with an immune checkpoint inhibitor (i.e., PD-1 or PD-L1), (4) enrolled or
eligible to be enrolled in the Lung Cancer Registry, and (5) able to speak and read English.
Because nearly all participants self-identified as patients, caregivers were not included in
analyses.
4.2. Procedure and Measures
The study received a waiver of IRB approval from Advarra IRB, as no identifiable
information was collected. Individuals self-reporting a diagnosis of lung cancer and treat-
ment with a PD-1 or PD-L1 inhibitor who participated in the Lung Cancer Registry were
invited to complete an online survey at one time point. Demographic information was
obtained from participants through use of a standardized self-report questionnaire. Vari-
ables assessed included age, race, ethnicity, marital status, and education (see Appendix A).
Severity of symptomatic toxicities during treatment with ICIs (e.g., fatigue, muscle pain,
rash) was assessed using a 5-point Likert scale with 0 = not at all and 4 = very much [31].
Symptomatic toxicities were identified based on a review of the literature as well as qual-
itative interviews with 14 patients, 7 caregivers, and 9 providers. Quality of life at the
time of assessment was evaluated with the FACT-G, a 27-item measure assessing physical
wellbeing (PWB), functional wellbeing (FWB), social wellbeing (SWB), and emotional well-
being (EWB) [32]. Items are summed to calculate a total score. Higher scores indicate better
quality of life. Additional self-reported disease and treatment variables evaluated included
comorbidities as assessed with the Charlson Comorbidity Index [33] (see Appendix A),
months on ICI, ICI regimen, treatment delays due to toxicity, ER visits due to toxicity, and
hospitalizations due to toxicity.
4.3. Statistical Analyses
Feasibility was defined as average patient recruitment per month. Acceptability was
defined as percentage of patients starting the survey who completed it. Descriptive statistics
were calculated using means, standard deviations, and percentages for sociodemographic
and clinical characteristics. Group differences were examined using ANOVA or chi square
tests, as appropriate. Participants’ FACT-G scores on the physical, functional, and emotional
wellbeing subscales were transformed to corresponding EORTC QLQ-C30 subscale scores
using published methodology [34] to compare quality of life in the current study to available
data from clinical trials of ICIs in NSCLC [23]. Post hoc comparisons identified where
any significant differences existed. Due to small cell sizes and to reduce the possibility of
Type I error, groups were not compared on symptomatic toxicities. All data analyses were
completed using SAS 9.4 (SAS Institute, Cary, NC, USA).
5. Conclusions
In summary, the results of the current study suggest that online patient registries
should be considered to explore PROs of novel anti-cancer agents. More research is
needed to validate patient-reported measures of symptomatic toxicities in this population
and understand their prevalence and longitudinal course in prospective studies. Future
prospective studies should also compare outcomes between patients on clinical trials
and those treated in the community. In addition, providers should consider asking about
common symptomatic toxicities that may be amenable to supportive care interventions. For
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example, physical activity has been shown to be beneficial in improving fatigue, arthralgias,
and myalgias in other cancer populations, as well as contributing to better sleep [35,36].
Randomized trials of physical activity and other interventions to improve symptomatic
toxicities of ICIs are also warranted.
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Appendix A








• American Indian or Alaska Native
• Asian
• Black or African American




Who is completing this survey?
What is the patient’s marital status?
What is the highest level of school the patient has COMPLETED?
What is the patient’s ethnic group?
Has the patient ever had a heart attack?
Has the patient ever been treated for heart failure?
Has the patient had an operation to unclog or bypass the arteries in his/her legs?
Has the patient had a stroke, cerebrovascular accident, blood clot or bleeding in the
brain, or transient ischemic attack (TIA)?
IF YES, does the patient have difficulty moving an arm or leg as a result of the stroke
or cerebrovascular accident?
Does the patient have asthma?
IF YES, does the patient take medicines for his/her asthma?
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Does the patient have emphysema, chronic bronchitis, or chronic obstructive lung
disease?
IF YES, does the patient take medicines for his/her lung disease?
Does the patient have stomach ulcers, or peptic ulcer disease?
IF YES, has this condition been diagnosed by endoscopy (where a doctor looks into
the patient’s stomach through a scope) or an upper GI or barium swallow study (where the
patient swallows chalky dye and then X-rays are taken)?
Does the patient have diabetes (high blood sugar)?
IF YES, has the diabetes caused problems with the patient’s kidneys?
IF YES, has the diabetes caused problems with the patient’s eyes, treated by an
ophthalmologist?
Has the patient ever had the following problems with their kidneys?
• Poor kidney function (blood tests show high creatinine)
• Have used hemodialysis or peritoneal dialysis
• Have received kidney transplantation
Does the patient have rheumatoid arthritis?
IF YES, does the patient take medications for it regularly?
Does the patient have lupus (systemic lupus erythematosus)?
Does the patient have polymyalgia rheumatica?
Does the patient have any of the following conditions? (Select all that apply.)
• Alzheimer’s Disease, or another form of dementia
• Cirrhosis, or serious liver damage
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